SCHEMBL2517899

SCHEMBL2517899

CCCC1CC(=O)N(C(Cc2ccc(OCc3ccccc3)cc2)C(N)=O)C1

nearest known ligand 0.44

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 3/20 0.44
PPARG P37231 3/20 0.44
PPARD Q03181 1/20 0.44
ADAM17 P78536 3/20 0.43
LTA4H P09960 2/20 0.42
S1PR5 Q9H228 1/20 0.42
ALOX5 P09917 2/20 0.41
LAP3 P28838 1/20 0.41
MAOB P27338 1/20 0.41
MMP13 P45452 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL563609 0.90 ALDH1A1 (0.46)
SCHEMBL2516304 0.86 ALDH1A1 (0.40)
SCHEMBL2521674 0.86 HDAC3 (0.40) MMP13
SCHEMBL2515243 0.85 GAA (0.46) PPARAPPARGPPARD
SCHEMBL2521663 0.85 OPRD1 (0.37)
SCHEMBL2518519 0.84 ALDH1A1 (0.39) PPARAPPARGPPARD
SCHEMBL563742 0.83 SLC1A1 (0.39)
SCHEMBL2518472 0.82 SLC6A3 (0.35)
SCHEMBL2519882 0.82 SMN1; SMN2 (0.38)
SCHEMBL2518655 0.82 ITGB2 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8034958-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UOB Pharma, S.A. (BE) 2011-10-11 US disclosed
US-20100222576-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB BIOPHARMA SPRL (BE) 2010-09-02 US disclosed
US-7692028-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2010-04-06 US disclosed
US-20080097109-A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB BIOPHARMA SPRL (BE) 2008-04-24 US disclosed
US-20050171187-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses DIFFERDING EDMOND (BE) 2005-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171187-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, OGDH, CYP1A2 PPARA 2571/4885PPARG 1903/4885PPARD 1127/4885
US-20080097109-A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, OGDH, CYP1A2 PPARA 2571/4885PPARG 1903/4885PPARD 1127/4885
US-20100222576-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, OGDH, CYP1A2 PPARA 2571/4885PPARG 1903/4885PPARD 1127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.